SAT-341-MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2019-04, Vol.70 (1), p.e789-e789
Main Authors: Chen, Hubert, Cremer, Karl, Bischoff, Eric, Lee, Kyoung-Jin, Littler, Rozalyn, Wetering, Jeroen van de, Arold, Gerhard, Duong, Minh-Nguyet, Song, Ken
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0168-8278
1600-0641
DOI:10.1016/S0618-8278(19)31571-3